The increase in UCP appears to be neuroprotective because UCP inhibitors exacerbate LRRK2 mutant pathology158 and overexpression of UCP2 protects against PD‐relevant neurotoxins, such as MPTP.158 Thus, UCPs may protect by diminishing the production of ROS by aberrant ETC function and compensate for diminished organelle antioxidant capacity. Here, LRRK2 is linked to Parkinson disease.